Literature DB >> 16132520

An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor.

Chun-Sheng Kang1, Pei-Yu Pu, Yan-He Li, Zhi-Yong Zhang, Ming-Zhe Qiu, Qiang Huang, Guang-Xiu Wang.   

Abstract

OBJECTIVES: To study the inhibitory effects of plasmid-based siRNA targeting human epidermal growth factor receptor (EGFR) on tumor proliferation and invasion of TJ905 glioblastoma cells.
METHODS: Two siRNA expression constructs targeting human EGFR extracellular domain (516-536) and catalytic domain (2400-2420) were transfected into TJ905 cell as mediated by Lipofectamine. Immunofluorescence assay and Western blotting were used to detect EGFR expression. Cell cycle was analyzed by flow cytometry, cell proliferative activity was measured by MTT assay. The expression and enzymatic activity of MMP9 were measured by Western blotting and gelatin zymography. Cell invasive capability was evaluated by Transwell method.
RESULTS: The expression of EGFR was knocked-down by 90 and 92, respectively in siRNA constructs transfected groups as indicated by immunofluorescence assay and Western blotting. The flow cytometric analysis showed that the S phase fraction (SPF) was lowered in both siRNAs transfected cells than that in parental cells and the cells transfected with empty vector. Compared to parental cells and the cells transfected with empty vector, the survival rates of glioma cells transfected with the siRNAs dramatically dropped down from the first day after implantation (P<0.05) as indicated by MTT assay. Meanwhile, the expression and enzymatic activity of MMP9 decreased significantly in siRNAs transfected in TJ905 cells, and cell invasive potential was also greatly inhibited in the Transwell study.
CONCLUSION: The siRNA expression constructs targeting EGFR could specifically suppress EGFR expression, inhibit cell growth, induce cell cycle arrest and suppress invasion. The plasmid-based siRNA targeting human EGFR approach should be a new strategy for gene therapy of malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132520     DOI: 10.1007/s11060-004-8322-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

1.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

2.  Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells.

Authors:  Peter Nagy; Donna J Arndt-Jovin; Thomas M Jovin
Journal:  Exp Cell Res       Date:  2003-04-15       Impact factor: 3.905

3.  Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo.

Authors:  P Pu; X Liu; A Liu; J Cui; Y Zhang
Journal:  J Neurosurg       Date:  2000-01       Impact factor: 5.115

4.  Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas.

Authors:  T Kubiatowski; T Jang; M B Lachyankar; R Salmonsen; R R Nabi; P J Quesenberry; N S Litofsky; A H Ross; L D Recht
Journal:  J Neurosurg       Date:  2001-09       Impact factor: 5.115

Review 5.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

6.  Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor.

Authors:  Torgeir Holen; Mohammed Amarzguioui; Merete T Wiiger; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

Review 7.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.

Authors:  Herbert B Newton
Journal:  Expert Rev Anticancer Ther       Date:  2003-10       Impact factor: 4.512

8.  Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer.

Authors:  Yun Zhang; Yu-Feng Zhang; Joshua Bryant; Andrew Charles; Ruben J Boado; William M Pardridge
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.

Authors:  Anita Lal; Chad A Glazer; Holly M Martinson; Henry S Friedman; Gary E Archer; John H Sampson; Gregory J Riggins
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing.

Authors:  Jens Harborth; Sayda M Elbashir; Kim Vandenburgh; Heiko Manninga; Stephen A Scaringe; Klaus Weber; Thomas Tuschl
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2003-04
View more
  12 in total

Review 1.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

Review 2.  Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

Authors:  Patrick Roth; Michael Weller
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A-431) cells.

Authors:  Y Tan; K H Chiow; D Huang; S H Wong
Journal:  Br J Pharmacol       Date:  2010-02-19       Impact factor: 8.739

4.  EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma.

Authors:  Marina Rolo Pinheiro da Rosa; Aline Semblano Carreira Falcão; Hellen Thais Fuzii; Maria Sueli da Silva Kataoka; André L R Ribeiro; Enrique Boccardo; Adriane Sousa de Siqueira; Ruy G Jaeger; João de Jesus Viana Pinheiro; Sérgio de Melo Alves Júnior
Journal:  Tumour Biol       Date:  2014-08-07

5.  Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β-catenin.

Authors:  Kui Wang; James O Park; Miqin Zhang
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

6.  Tumor-targeted delivery of siRNA by self-assembled nanoparticles.

Authors:  Shyh-Dar Li; Yun-Ching Chen; Michael J Hackett; Leaf Huang
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

7.  ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.

Authors:  Na Tosha N Gatson; Shiao-Pei S Weathers; John F de Groot
Journal:  CNS Oncol       Date:  2015-12-15

8.  c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro.

Authors:  Sheng-Hua Chu; Dong-Fu Feng; Hong Zhang; Er-Tao Chen; Zhi-Xin Duan; Xue-Yuan Li; Jia Li; Yan-Bin Ma; Zhi-An Zhu; Jian-Hua Qiu
Journal:  J Neurooncol       Date:  2009-01-24       Impact factor: 4.130

9.  Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.

Authors:  Monika Witusik-Perkowska; Piotr Rieske; Krystyna Hułas-Bigoszewska; Magdalena Zakrzewska; Robert Stawski; Dominika Kulczycka-Wojdala; Michał Bieńkowski; Ewelina Stoczyńska-Fidelus; Sylwia M Grešner; Sylwester Piaskowski; Dariusz J Jaskólski; Wielisław Papierz; Krzysztof Zakrzewski; Maciej Kolasa; James W Ironside; Paweł P Liberski
Journal:  J Neurooncol       Date:  2010-08-29       Impact factor: 4.130

10.  Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.

Authors:  Erin B Dickerson; William H Blackburn; Michael H Smith; Laura B Kapa; L Andrew Lyon; John F McDonald
Journal:  BMC Cancer       Date:  2010-01-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.